Bavarian Nordic Announces Initiation of a Global Phase 3 Clinical Trial of its COVID-19 Booster Vaccine Candidate
- First subject vaccinated in Phase 3 clinical trial evaluating potential of the VLP-based candidate, ABNCoV2 as a booster COVID-19 vaccine
- Trial will assess non-inferiority of ABNCoV2 compared to Comirnaty® in terms of neutralizing antibodies against the SARS-CoV-2 (Wuhan wild type) as the primary endpoint, and other variants of concern as secondary endpoints
COPENHAGEN, Denmark, September 2, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today the dosing of the first subject in the Phase 3 clinical trial of ABNCoV2, a VLP-based, non-adjuvanted COVID-19 booster vaccine candidate.
The double-blind, controlled Phase 3 clinical trial will enroll approximately 4,000 adult subjects who either previously completed primary vaccination or have already received one booster dose of a licensed COVID-19 vaccine. The trial consists of two groups. An active controlled group will be conducted in Denmark and Belgium and will start enrollment later this fall. Subjects in this group will be randomized to receive either a single 100 µg dose of ABNCoV2, or a single 30 µg adult booster dose of Comirnaty. The second group, which has now started enrollment in the U.S., will evaluate the safety and tolerability of the vaccine in subjects receiving a single 100 µg dose of ABNCoV2.
Initial trial results are expected towards the end of 2022, which will allow for a rolling submission to the regulatory authorities, aiming to obtain approval of the vaccine in 2023.
Paul Chaplin, President and Chief Executive Officer of Bavarian Nordic, said: “Advancing ABNCoV2 into Phase 3 trials represents another significant step in the progression of our pipeline this year, and not least an important contribution to the development of a universal COVID-19 booster vaccine. In clinical trials to-date, ABNCoV2 has shown potential to boost neutralizing antibodies against SARS-CoV-2, including variants of concern, to levels associated with a high degree of protection. We hope that the Phase 3 trial will confirm these strong results, thus unleashing the potential of ABNCoV2 as a differentiated approach without the need for adaptation”.
The Phase 3 development of ABNCoV2 is partly funded through an agreement with the Danish State.
ABNCoV2 is a next-generation COVID-19 vaccine candidate, initially developed by AdaptVac, Denmark, using their proprietary capsid virus like particle (cVLP) technology. Bavarian Nordic has licensed the global commercialization rights to the vaccine and has assumed the responsibility for further clinical development towards licensure.
ABNCoV2 has shown to be highly immunogenic in relevant preclinical models inducing a durable and highly protective response from a COVID-19 challenge. Results from a Phase 2 trial has confirmed the ability of ABNCoV2 to significantly boost antibody titers as previously demonstrated in preclinical and Phase 1 clinical trials, and also confirm the potential of ABNCoV2 to boost antibody titers against SARS-CoV2 variants of concern.
About Bavarian Nordic
Bavarian Nordic is a fully integrated vaccines company focused on the development, manufacturing and commercialization of life-saving vaccines. We are a global leader in smallpox vaccines and have been a long-term supplier to the U.S. Government of a non-replicating smallpox vaccine, which has been approved by the FDA, also for the protection against monkeypox. The vaccine is also approved in Europe and Canada. Our commercial product portfolio furthermore contains market-leading vaccines against rabies and tick-borne encephalitis. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates designed to save and improve lives by unlocking the power of the immune system, including an Ebola vaccine, which is licensed to the Janssen Pharmaceutical Companies of Johnson & Johnson. We are also committed to the development of a next generation COVID-19 vaccine. For more information visit www.bavarian-nordic.com.
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
Europe: Rolf Sass Sørensen, Vice President Investor Relations, Tel: +45 61 77 47 43
US: Graham Morrell, Paddock Circle Advisors, firstname.lastname@example.org, Tel: +1 781 686 9600
Company Announcement no. 33 / 2022
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Suspension på grund af tekniske problemer.2.12.2022 09:33:19 CET | pressemeddelelse
På grund af tekniske problemer kan der i øjeblikket ikke beregnes indre værdi til Nasdaq for alle Handelsinvests afdelinger. ISIN Afdeling SHORT NAME DK0010232768 Handelsinvest Danmark HAIDK DK0060040087 Handelsinvest Danske Obligationer HAIDKOBL DK0060774479 Handelsinvest Defensiv 10 (AK) HAID10A DK0060774552 Handelsinvest Defensiv 30 (AK) HAID30A DK0015809065 Handelsinvest Europa HAIEU DK0015994453 Handelsinvest Fjernøsten HAIFJ DK0060014918 Handelsinvest Højrentelande HAIHRTL DK0060159218 Handelsinvest Nordamerika HAINAM DK0060048064 Handelsinvest Norden HAINOR DK0060774636 Handelsinvest Offensiv 60 (AK) HAIO60A DK0060774719 Handelsinvest Offensiv 80 (AK) HAIOF80A DK0010157296 Handelsinvest Verden HAIVER DK0060262061 Handelsinvest Virksomhedsobligationer HAIVOB DK0061406964 Handelsinvest High Yield Bonds HAIHYB DK0061140910 Handelsinvest Defensiv 10 Akkumulerende (AK) HAID10AKK DK0061141058 Handelsinvest Offensiv 80 Akkumulerende (AK) HAIO80AKK Yderligere oplysninger kan fås ved hen
Municipality Finance issues EUR 5 million notes under its MTN programme2.12.2022 09:00:00 CET | Press release
Municipality Finance Plc Stock exchange release 2 December 2022 at 10:00am (EET) Municipality Finance issues EUR 5million notes under its MTN programme Municipality Finance Plc issues EUR 5 million notes on 5 December 2022. The maturity date of the notes is 5 December 2029. MuniFin has a right, but no obligation, to redeem the notes early on 5 December 2025. The notes bear interest at a fixed rate of 3.05% per annum. The notes are issued under MuniFin’s EUR 45 billion programme for the issuance of debt instruments. The offering circular, the supplemental offering circular and the final terms of the notes are available in English on the company's website at www.munifin.fi/investor-relations. MuniFin has applied for the notes to be admitted to trading on the Helsinki Stock Exchange maintained by Nasdaq Helsinki. The public trading is expected to commence on 5 December 2022. DZ Bank AG acts as the Dealer for the issue of the notes. MUNICIPALITY FINANCE PLC Further information: Joakim Holm
Financial calendar 2023 for FirstFarms A/S2.12.2022 09:00:00 CET | Press release
FirstFarms A/S’ Board of Directors has adopted the following financial calendar for 2023: 24 March 2023 Annual report 2022 25 April 2023 Annual general meeting 17 May 2023 Interim financial report 1 January – 31 March 202330 August 2023 Interim financial report 1 January – 30 June 202329 November 2023 Interim financial report 1 January – 30 September 2023 Proposals from the shareholders for discussion on the annual general meeting 25 April 2023 shall be in the Board of Directors’ possession at the latest 14 March 2023. Best regards, FirstFarms A/S For further information: Please visit our website www.firstfarms.com or contact CEO Anders H. Nørgaard on telephone +45 75 86 87 87. About FirstFarms: FirstFarms is a Danish stock exchange listed company. We operate FirstFarms with responsibility for the surrounding communities, and we deliver highest quality which is primarily sold locally. We act on new opportunities, that create value for our investors and for the surroundings. Every day,
Finanskalender 2023 for FirstFarms A/S2.12.2022 09:00:00 CET | pressemeddelelse
Bestyrelsen for FirstFarms A/S har vedtaget følgende finanskalender for 2023: 24. marts 2023 Årsregnskab 202225. april 2023 Generalforsamling17. maj 2023 Delårsrapport 1. januar – 31. marts 202330. august 2023 Delårsrapport 1. januar – 30. juni 202329. november 2023 Delårsrapport 1. januar – 30. september 2023 Forslag fra aktionærer til behandling på generalforsamlingen den 25. april 2023 skal være bestyrelsen i hænde senest den 14. marts 2023. Med venlig hilsen FirstFarms A/S For yderligere information: Se venligst vores hjemmeside www.firstfarms.dk eller kontakt adm. direktør Anders H. Nørgaard på telefon 75 86 87 87. Om FirstFarms: FirstFarms er et dansk børsnoteret selskab. Vi driver FirstFarms med ansvar for de omkringliggende samfund, og vi leverer højeste kvalitet, som primært afsættes lokalt. Vi handler på nye muligheder, der skaber værdi for vores investorer og for omverdenen. Vi arbejder hver dag på at skabe en mere bæredygtig virksomhed. Vedhæftet fil (27) Finanskalender 202
Edenred Capital invests in 5Mins AI, the “TikTok-style” learning platform2.12.2022 08:31:07 CET | Press release
Press release 2 December 2022 Edenred Capital invests in 5Mins AI, the “TikTok-style” learning platform The Edenred Group has invested in 5Mins AI, via Edenred Capital, its venture capital arm.5MinsAI is a gamified learning platform reinventing employee upskilling through a “TikTok-style” mobile-led experience. Edenred Capital invested in this seed round alongsideAlbionVC. This investment aims to drive 5Mins AI’s product development and expand its global customer base. 5Mins AI is a UK-based company founded in 2021, providing short-form learning for companies via a mobile app that delivers personalised, micro-sized videos in TikTok format, promoting continuous learning. The platform features 15,000+ bite-sized lessons from 150+ educators and coaches worldwide covering 100+ essential technical and power skills for the workplace. Since going to market in March 2022, more than 100,000+ lessons have been watched on the platform and 5Mins AI’s annual recurring revenue has grown 20x. Edenred